Daniel O'Hagan, Siddhartha Shandilya, Lincoln J Hopkins, Patricia A Hahn, Sebastian P Fuchs, Jose M Martinez-Navio, Michael D Alpert, Mathew R Gardner, Ronald C Desrosiers, Guangping Gao, Jeffrey D Lifson, Michael Farzan, Amir Ardeshir, Mauricio A Martins
{"title":"In vivo evolution of env in SHIV-AD8<sub>EO</sub>-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig.","authors":"Daniel O'Hagan, Siddhartha Shandilya, Lincoln J Hopkins, Patricia A Hahn, Sebastian P Fuchs, Jose M Martinez-Navio, Michael D Alpert, Mathew R Gardner, Ronald C Desrosiers, Guangping Gao, Jeffrey D Lifson, Michael Farzan, Amir Ardeshir, Mauricio A Martins","doi":"10.1016/j.ymthe.2024.12.015","DOIUrl":null,"url":null,"abstract":"<p><p>eCD4-Ig is an entry inhibitor of the human immunodeficiency virus (HIV) that mimics the engagement of both CD4 and CCR5 with the HIV Envelope (Env) protein, a property which imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in simian-HIV (SHIV)-AD8<sub>EO</sub>-infected rhesus macaques (RMs) treated with adeno-associated vectors (AAV) encoding eCD4-Ig. In one RM, setpoint viremia plateaued at 1,000 vRNA copies/ml, despite concomitant serum concentrations of eCD4-Ig in the 60-110 μg/ml range, implying that the virus had gained partial eCD4-Ig resistance. Env mutations occurring prominently in this animal were cloned and further characterized. Three of these mutations (R315G, A436T, G471E) were sufficient to confer substantial resistance to eCD4-Ig-mediated neutralization onto the parental Env, accompanied by a marked loss of viral fitness. This resistance was not driven by decreased CD4 affinity, subverted sulfopeptide mimicry, changes to coreceptor tropism, or by a gain of CD4 independence. Rather, our data argue that the Env evolving in this animal attained eCD4-Ig resistance by decreasing triggerability, stabilizing state-2, and changing the nature of its relationship to the host CD4.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":""},"PeriodicalIF":12.1000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2024.12.015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
eCD4-Ig is an entry inhibitor of the human immunodeficiency virus (HIV) that mimics the engagement of both CD4 and CCR5 with the HIV Envelope (Env) protein, a property which imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in simian-HIV (SHIV)-AD8EO-infected rhesus macaques (RMs) treated with adeno-associated vectors (AAV) encoding eCD4-Ig. In one RM, setpoint viremia plateaued at 1,000 vRNA copies/ml, despite concomitant serum concentrations of eCD4-Ig in the 60-110 μg/ml range, implying that the virus had gained partial eCD4-Ig resistance. Env mutations occurring prominently in this animal were cloned and further characterized. Three of these mutations (R315G, A436T, G471E) were sufficient to confer substantial resistance to eCD4-Ig-mediated neutralization onto the parental Env, accompanied by a marked loss of viral fitness. This resistance was not driven by decreased CD4 affinity, subverted sulfopeptide mimicry, changes to coreceptor tropism, or by a gain of CD4 independence. Rather, our data argue that the Env evolving in this animal attained eCD4-Ig resistance by decreasing triggerability, stabilizing state-2, and changing the nature of its relationship to the host CD4.
期刊介绍:
Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.